Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

The effect and application of gentioside in the treatment of pulmonary arterial hypertension

A technology for pulmonary arterial hypertension and gentioside, which is applied in the field of preparation of drugs for the prevention and treatment of pulmonary hypertension, and can solve the problems of no reports of gentioside being found

Inactive Publication Date: 2015-12-30
FOURTH MILITARY MEDICAL UNIVERSITY
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] According to the inventor's data retrieval, no report has been found so far that gentioside is used to prepare the medicine for the treatment of PAH

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • The effect and application of gentioside in the treatment of pulmonary arterial hypertension
  • The effect and application of gentioside in the treatment of pulmonary arterial hypertension
  • The effect and application of gentioside in the treatment of pulmonary arterial hypertension

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Take 50g picrogentioside, add 200g starch, 150g lactose, mix well, add 2% dextrin aqueous solution to make soft material, granulate with 24 mesh sieve, dry at 50°C, granulate with 24 mesh sieve, add 5g stearin Magnesium acid, mixed evenly, pressed into 1000 tablets, that is to say.

Embodiment 2

[0024] Take 50g picrogentioside, add 300g starch, 50g microcrystalline cellulose, mix well, add 2% dextrin aqueous solution to make soft material, granulate with 24 mesh sieve, dry at 50 °C, granulate with 24 mesh sieve, add 15g of talcum powder, mixed evenly, pressed into 1000 pieces, that is to say.

Embodiment 3

[0026] Take 50g of picrogentioside, add 200g of starch and 350g of lactose, mix well, add a well-mixed 2% dextrin aqueous solution to bind, make a soft material, pass through a 24 mesh sieve, dry at 50°C, granulate, divide Packed into 1000 bags, that is.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a new function of amarogentin for preventing or treating pulmonary arterial hypertension, and belongs to the technical field of pharmacological action of a component. It is discovered that the amarogentin has an effect of obviously relieving myocardial hypertrophy, myocardial edema, pulmonary arteriolar wall thickening and stenosis caused by hypoxic pulmonary hypertension. Therefore, the amarogentin can be used for preparing a medicine for preventing and treating related cardiovascular diseases caused by the pulmonary arterial hypertension. The medicine can be prepared into tablet, capsule, granule, pill, powder, injection, emulsion or other pharmaceutically acceptable dosage forms.

Description

technical field [0001] The invention relates to the new action of gentioside in the treatment of pulmonary arterial hypertension and its application in the preparation of medicines for the prevention and treatment of pulmonary arterial hypertension, belonging to the technical field of pharmacological action of compounds. Background technique [0002] Pulmonary Arterial Hypertension (PAH) is a kind of extremely malignant progressive disease characterized by progressive increase of pulmonary vascular resistance, eventually leading to right heart failure and even death. In the latest evidence-based clinical practice guidelines for the diagnosis and treatment of pulmonary arterial hypertension issued by the American College of Chest Physicians (ACCP), it is defined as mean pulmonary arterial pressure ≥ 25 mmHg, capillary pressure or left atrial pressure ≤ 15 mmHg. PAH is divided into two types: primary (PPH) and secondary (SPH). Clinically, the main manifestations are exertional...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/7048A61P9/12A61P11/00
Inventor 曹蔚王四旺李小强沈歆谢艳华杨倩
Owner FOURTH MILITARY MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com